Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $13,954 | $12,443 | $11,027 | $13,650 |
| - Cash | $340 | $264 | $194 | $233 |
| + Debt | $428 | $439 | $448 | $455 |
| Enterprise Value | $14,042 | $12,618 | $11,280 | $13,872 |
| Revenue | $795 | $688 | $573 | $628 |
| % Growth | 15.6% | 20.1% | -8.8% | – |
| Gross Profit | $781 | $676 | $563 | $618 |
| % Margin | 98.2% | 98.4% | 98.4% | 98.5% |
| EBITDA | $300 | $153 | $31 | $182 |
| % Margin | 37.7% | 22.2% | 5.5% | 28.9% |
| Net Income | $210 | $108 | $8 | $103 |
| % Margin | 26.4% | 15.6% | 1.4% | 16.4% |
| EPS Diluted | 2.04 | 1.06 | 0.08 | 1 |
| % Growth | 92.5% | 1,225% | -92% | – |
| Operating Cash Flow | $228 | $102 | $65 | $243 |
| Capital Expenditures | -$13 | -$13 | -$11 | -$7 |
| Free Cash Flow | $214 | $90 | $54 | $235 |